Kingmed Diagnostics(SH:603882) Zheng Quan Shi Bao Wang·2025-08-22 13:41Core Insights - The core viewpoint of the articles highlights the performance and strategic initiatives of Kingmed Diagnostics (金域医学) in the medical testing industry, particularly in the context of its financial results and innovative approaches to enhance operational efficiency and market competitiveness. Financial Performance - In the first half of 2025, Kingmed Diagnostics reported total revenue of 2.997 billion yuan, with a net profit attributable to shareholders of -85 million yuan due to credit impairment losses of 272 million yuan. However, the operating cash flow improved significantly, reaching 350 million yuan, a year-on-year increase of 920% [1]. Industry Trends - The medical testing industry is undergoing a deep adjustment period driven by multiple factors, including healthcare reform, technological advancements, ecological restructuring, and data application [1]. Product and Service Innovation - Kingmed Diagnostics launched several high-cost performance products in oncology, infectious diseases, and neurology, achieving significant revenue growth: the "惠民3000" series for tumors grew by 85%, the Meta series for infectious diseases by 49.99%, and the early screening series for Alzheimer's disease by 68.43%. The revenue from tertiary hospitals increased to 51.18%, up by 5.43 percentage points year-on-year [2]. Collaborative Efforts - The company has established partnerships with over 210 hospitals, universities, and research institutions, collaborating on multi-center research and joint laboratory construction with top-tier hospitals [2]. AI Integration - Kingmed Diagnostics has initiated the "AI IN ALL" program, developing 55 intelligent applications to enhance business processes. AI-assisted diagnostics were utilized 2.2 million times in a year, improving laboratory efficiency significantly, with a 70% increase in report issuance efficiency for the tumor molecular reporting system [3]. Data-Driven Growth - The company has accumulated over 3 billion medical testing data samples and successfully launched 21 data products on data exchanges in major cities. It was selected as a pilot for the national trusted data space innovation development, being the only medical institution to achieve this [4]. Commercial Model Exploration - Kingmed Diagnostics has developed a compliant commercial model for the circulation of medical testing data, collaborating on 20 projects with various entities, including public health departments and pharmaceutical companies. The company is actively involved in major public health initiatives, including infectious disease monitoring and emergency response [5].